Previous Close | 2,070.00 |
Open | 2,098.00 |
Bid | 2,066.00 x N/A |
Ask | 2,070.00 x N/A |
Day's Range | 2,069.00 - 2,147.00 |
52 Week Range | 1,540.00 - 2,329.00 |
Volume | |
Avg. Volume | 39,624 |
Market Cap | 1.217B |
Beta (5Y Monthly) | 0.25 |
PE Ratio (TTM) | 38.51 |
EPS (TTM) | 0.55 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for KMDA.TA
By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On March 6, 2024, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the fourth quarter and full year 2023 and provided a business update. Kamada reported revenues of $142.5 million, which met the company’s previously announced guidance, and was a 10% increase compared to fiscal year 2022. The increase was
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript March 6, 2024 Kamada Ltd. beats earnings expectations. Reported EPS is $0.09, expectations were $0.05. KMDA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Kamada Ltd.’s Fourth Quarter and […]
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear Shareholders, Colleagues and Business Partners: The recently completed 2023 was another successful period in our com